View in EDS

A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies.

Saved in:
Bibliographic Details
Title: A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies.
Authors: Piha-Paul S; Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Olwill SA; Department of Research and Development, Pieris Pharmaceuticals GmbH, Bavaria, Germany., Hamilton E; Department of Oncology, Sarah Cannon Research Institute/Tennessee Oncology, LLC, Nashville, Tennessee., Tolcher A; NEXT Oncology, San Antonio, Texas., Pohlmann P; Department of Medicine, Georgetown University Lombardi Comprehensive Cancer Center, Washington, District of Columbia., Liu SV; Department of Medicine, Georgetown University Lombardi Comprehensive Cancer Center, Washington, District of Columbia., Wurzenberger C; Department of Research and Development, Pieris Pharmaceuticals GmbH, Bavaria, Germany., Hasenkamp LC; Department of Research and Development, Pieris Pharmaceuticals GmbH, Bavaria, Germany., Hansbauer EM; Department of Research and Development, Pieris Pharmaceuticals GmbH, Bavaria, Germany., Shroff R; Department of Medicine, University of Arizona Cancer Center, Tucson, Arizona., Hurvitz S; Department of Medicine, University of California Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, California., Krishnamurthy A; University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania., Patnaik A; Department of Phase I Research, The START Center for Cancer Research, San Antonio, Texas., Hahn N; Department of Oncology and Urology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland., Kumar R; Department of Research and Development, Pieris Pharmaceuticals GmbH, Bavaria, Germany., Duerr M; Department of Research and Development, Pieris Pharmaceuticals GmbH, Bavaria, Germany., Zettl M; Department of Research and Development, Pieris Pharmaceuticals GmbH, Bavaria, Germany., Aviano K; Department of Research and Development, Pieris Pharmaceuticals, Inc., Boston, Massachusetts., Matis L; Department of Research and Development, Pieris Pharmaceuticals, Inc., Boston, Massachusetts., Bruns I; Department of Research and Development, Pieris Pharmaceuticals, Inc., Boston, Massachusetts., Ku G; Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2025 Jan 17; Vol. 31 (2), pp. 288-298.
Publication Type: Journal Article; Multicenter Study; Clinical Trial, Phase I
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39235868
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Piha-Paul+S%22">Piha-Paul S</searchLink>; Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Olwill+SA%22">Olwill SA</searchLink>; Department of Research and Development, Pieris Pharmaceuticals GmbH, Bavaria, Germany.<br /><searchLink fieldCode="AU" term="%22Hamilton+E%22">Hamilton E</searchLink>; Department of Oncology, Sarah Cannon Research Institute/Tennessee Oncology, LLC, Nashville, Tennessee.<br /><searchLink fieldCode="AU" term="%22Tolcher+A%22">Tolcher A</searchLink>; NEXT Oncology, San Antonio, Texas.<br /><searchLink fieldCode="AU" term="%22Pohlmann+P%22">Pohlmann P</searchLink>; Department of Medicine, Georgetown University Lombardi Comprehensive Cancer Center, Washington, District of Columbia.<br /><searchLink fieldCode="AU" term="%22Liu+SV%22">Liu SV</searchLink>; Department of Medicine, Georgetown University Lombardi Comprehensive Cancer Center, Washington, District of Columbia.<br /><searchLink fieldCode="AU" term="%22Wurzenberger+C%22">Wurzenberger C</searchLink>; Department of Research and Development, Pieris Pharmaceuticals GmbH, Bavaria, Germany.<br /><searchLink fieldCode="AU" term="%22Hasenkamp+LC%22">Hasenkamp LC</searchLink>; Department of Research and Development, Pieris Pharmaceuticals GmbH, Bavaria, Germany.<br /><searchLink fieldCode="AU" term="%22Hansbauer+EM%22">Hansbauer EM</searchLink>; Department of Research and Development, Pieris Pharmaceuticals GmbH, Bavaria, Germany.<br /><searchLink fieldCode="AU" term="%22Shroff+R%22">Shroff R</searchLink>; Department of Medicine, University of Arizona Cancer Center, Tucson, Arizona.<br /><searchLink fieldCode="AU" term="%22Hurvitz+S%22">Hurvitz S</searchLink>; Department of Medicine, University of California Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, California.<br /><searchLink fieldCode="AU" term="%22Krishnamurthy+A%22">Krishnamurthy A</searchLink>; University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Patnaik+A%22">Patnaik A</searchLink>; Department of Phase I Research, The START Center for Cancer Research, San Antonio, Texas.<br /><searchLink fieldCode="AU" term="%22Hahn+N%22">Hahn N</searchLink>; Department of Oncology and Urology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.<br /><searchLink fieldCode="AU" term="%22Kumar+R%22">Kumar R</searchLink>; Department of Research and Development, Pieris Pharmaceuticals GmbH, Bavaria, Germany.<br /><searchLink fieldCode="AU" term="%22Duerr+M%22">Duerr M</searchLink>; Department of Research and Development, Pieris Pharmaceuticals GmbH, Bavaria, Germany.<br /><searchLink fieldCode="AU" term="%22Zettl+M%22">Zettl M</searchLink>; Department of Research and Development, Pieris Pharmaceuticals GmbH, Bavaria, Germany.<br /><searchLink fieldCode="AU" term="%22Aviano+K%22">Aviano K</searchLink>; Department of Research and Development, Pieris Pharmaceuticals, Inc., Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Matis+L%22">Matis L</searchLink>; Department of Research and Development, Pieris Pharmaceuticals, Inc., Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Bruns+I%22">Bruns I</searchLink>; Department of Research and Development, Pieris Pharmaceuticals, Inc., Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Ku+G%22">Ku G</searchLink>; Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229502500%22">Clinical cancer research : an official journal of the American Association for Cancer Research</searchLink> [Clin Cancer Res] 2025 Jan 17; Vol. 31 (2), pp. 288-298.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Multicenter Study; Clinical Trial, Phase I
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%22">American Association for Cancer Research </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9502500 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1557-3265 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210780432%22">10780432 </searchLink><i>NLM ISO Abbreviation: </i>Clin Cancer Res <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39235868
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/1078-0432.CCR-24-1552
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 288
    Titles:
      – TitleFull: A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Piha-Paul S
      – PersonEntity:
          Name:
            NameFull: Olwill SA
      – PersonEntity:
          Name:
            NameFull: Hamilton E
      – PersonEntity:
          Name:
            NameFull: Tolcher A
      – PersonEntity:
          Name:
            NameFull: Pohlmann P
      – PersonEntity:
          Name:
            NameFull: Liu SV
      – PersonEntity:
          Name:
            NameFull: Wurzenberger C
      – PersonEntity:
          Name:
            NameFull: Hasenkamp LC
      – PersonEntity:
          Name:
            NameFull: Hansbauer EM
      – PersonEntity:
          Name:
            NameFull: Shroff R
      – PersonEntity:
          Name:
            NameFull: Hurvitz S
      – PersonEntity:
          Name:
            NameFull: Krishnamurthy A
      – PersonEntity:
          Name:
            NameFull: Patnaik A
      – PersonEntity:
          Name:
            NameFull: Hahn N
      – PersonEntity:
          Name:
            NameFull: Kumar R
      – PersonEntity:
          Name:
            NameFull: Duerr M
      – PersonEntity:
          Name:
            NameFull: Zettl M
      – PersonEntity:
          Name:
            NameFull: Aviano K
      – PersonEntity:
          Name:
            NameFull: Matis L
      – PersonEntity:
          Name:
            NameFull: Bruns I
      – PersonEntity:
          Name:
            NameFull: Ku G
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 17
              M: 01
              Text: 2025 Jan 17
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1557-3265
          Numbering:
            – Type: volume
              Value: 31
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: Clinical cancer research : an official journal of the American Association for Cancer Research
              Type: main
ResultId 1